RSCM
KLDO

Rock Springs Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Rock Springs Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,050
Closed -$753K – 143
2019
Q3 		$753K Hold
100,050
– – 0.03% 136
2019
Q2 		$1.16M Hold
100,050
– – 0.04% 129
2019
Q1 		$1.45M Buy
+100,050
New +$1.38M 0.06% 125

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Rock Springs Capital Management's KLDO Position: Q4 2019 in Review

Rock Springs Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2019, closing a stake of 100,050 shares — an estimated $753K sold.

Rock Springs Capital Management first reported a position in KLDO in Q1 2019 and held it in 3 quarters. The position peaked at $1.45M in Q1 2019. 45 funds tracked by Wall St. Rank hold KLDO as of Q4 2019.

  • Rock Springs Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Rock Springs Capital Management sold 100,050 Kaleido Biosciences, Inc. Common Stock shares in Q4 2019, an estimated $753K.
  • Rock Springs Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Rock Springs Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $1.45M in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2019.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.